Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 9/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NQO2 | P16083 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5073633 | 0.84 | MTNR1A (0.71) | MTNR1AMTNR1BKMT2AMEN1 | |
| SCHEMBL4463389 | 0.81 | SMN1; SMN2 (0.57) | MTNR1AMTNR1BKMT2ANQO2 | |
| SCHEMBL5072982 | 0.81 | POLB (0.58) | MTNR1AMTNR1BPOLB | |
| SCHEMBL6678463 | 0.80 | ABCC9 (0.54) | MTNR1AMTNR1BKMT2AMEN1 | |
| SCHEMBL6541155 | 0.78 | MTNR1A (0.48) | MTNR1AMTNR1BKMT2AMEN1 | |
| SCHEMBL6676699 | 0.78 | MTNR1A (0.48) | MTNR1AMTNR1BKMT2AMEN1 | |
| SCHEMBL9632174 | 0.77 | POLB (0.57) | POLB | |
| SCHEMBL1095100 | 0.76 | MTNR1A (0.62) | MTNR1AMTNR1BKMT2AMEN1POLB | |
| SCHEMBL6541474 | 0.74 | POLB (0.50) | MTNR1AMTNR1BKMT2APOLB | |
| SCHEMBL140038 | 0.73 | SMN1; SMN2 (0.67) | MTNR1AMTNR1BKMT2ANQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
| WO-2004045610-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD (JP) | 2004-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106653-A1 | Aminoalcohol derivatives | FANCD2, FANCI, HRH2 | MTNR1A 1674/4885MTNR1B 1266/4885KMT2A 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.